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Biphasie glomerular hypertrophy in rats administered puromycin
aminonucleoside. Recent evidence suggests that glomerular hypertrophy
is a key event in the development of focal and segmental glomerulosele-
rosis and hyalinosis (FSGS) in humans and in many experimental models
of FSGS. The initial aim of the present study was to determine if
glomerular hypertrophy occurs in a puromycin aminonucleoside (PAN)
model of FSGS, previously considered not to involve glomerular hyper-
trophy. Upon identifying significant glomerular hypertrophy, our second
aim was to determine the contribution of glomerular capillary growth to
this hypertrophy. Female Sprague-Dawley rats (approximately 200 g) were
administered either PAN (2 mg/tOO g body wt) subcutaneously, or an
equivalent volume of 0.9% saline at weeks 0, 1, 2, 4, 6, 8 and 10. Tissue was
analyzed at weeks 7 and 13. Unbiased stereological methods were used to
estimate a range of glomerular parameters. Mean glomerular tuft volume
in PAN-treated rats was 48% greater than in saline-treated rats at seven
weeks, and 63% greater at 13 weeks. Similar results were found for mean
renal corpuscle volume. FSGS was absent at seven weeks and minor at 13
weeks. Two-way analysis of variance indicated: significant effects (P < 0.05
at least) of PAN on capillary length per glomerulus, capillary surface area
per glomerulus, capillary diameter and length of capillaries per unit
volume of glomerulus; and significant effects of time on capillary diameter,
capillary length per unit volume of glomerulus and capillary surface area
per unit volume of glomerulus. The mean length of capillaries per
glomerulus was 45% greater in PAN-treated rats at week 7 and 22%
greater in PAN-treated rats at week 13. Taken together, these results
indicate a biphasic pattern of glomerular hypertrophy in this model. In the
first phase (to 7 weeks), an increase in capillary length contributes to
glomerular hypertrophy. In the second phase (7 to 13 weeks), the
continued glomerular enlargement appears more likely to be due to an
increase in capillary diameter and/or mesangial matrix expansion.
Focal and segmental glomerulosclerosis and hyalinosis (FSGS)
is a chronic condition associated with progressive loss of function-
ing glomeruli. While the pathogenesis of primary FSGS remains
unknown, glomcrular lesions resembling those seen in FSGS arise
following a wide range of primary insults to the kidney.
Evidence from both human and animal studies suggests that
glomerular hypcrtrophy may play a key role in the development of
both primary and secondary forms of FSGS. Glomerular hyper-
trophy has been reported in patients with glomeruloscierosis
associated with oligomcganephronia [1], diabetic nephropathy [2],
reflux nephropathy [3], pre-eclampsia [4] and following renal
transplantation [51. Fogo et al [61 found that minimal change
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disease patients with hypertrophied glorneruli had a much greater
risk of developing FSGS at a later stage than minimal change
patients with normal-sized glomeruli. Glomerular hypertrophy
has been reported in a wide variety of animal models, including
mice that are transgenic for growth hormone [7], and in rats
following partial renal ablation [8—111.
One model of FSGS previously considered not to involve
glomerular hypertrophy is the multiple puromycin aminonucleo-
side (PAN) model utilized by Grond, Weening and Elema [12]
and Marinides et al [13]. In this model, FSGS is observed by 12
weeks. The initial aim of the present study was to determine if
glomerular hypertrophy occurred in this model of FSGS, and if so,
if the glomerular hypertrophy preceded, accompanied or followed
the development of FSGS. We used recently developed stereo-
logical methods to estimate glomerular volume [14]. These meth-
ods provide unbiased and precise estimates of glomerular volume
and are not influenced by heterogeneity in glomerular size, an
important consideration in this study.
On finding pronounced glomerular hypertrophy prior to FSGS,
we investigated the contribution of capillary growth to this
hypertrophy. Capillaries constitute approximately 40% of the
volume of the glomerular tuft [15], and therefore any increase in
this glomerular compartment would have a major effect on
glomerular volume. Again using unbiased stereological methods
we found that significant capillary growth contributed to the
glomerular hypertrophy.
Methods
Animals and tissue processing
Female Sprague-Dawley rats weighing approximately 200 g
were administered subcutaneous injections of puromycin amino-
nucleoside (PAN; Sigma Chemical Company, St. Louis, MO,
USA) at a dose of 2 mg/lOU g body wt, or an equivalent volume of
0.9% saline. Seven injections were given over a period of 10
weeks, at weeks 0, 1, 2, 4, 6, 8 and 10, as described by Grond et al
[12] and Marinides et al [13]. All experiments were conducted in
accordance with the "Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes."
Rats were kept in metabolic cages for two day periods through-
out the experiment, to obtain urine samples for determination of
daily protein excretion rates. Protein concentrations were mea-
sured using the Bio-Rad protein determination system (Bio-Rad
Laboratories, Hercules, CA, USA) [16].
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Seven and thirteen weeks after the first injection, rats were
anaesthetised with pentobarbitol (Nembutal, Abbott Laborato-
ries, Sydney, Australia), and the kidneys were perfused with
Hanks' balanced salt solution for one to two minutes, followed by
4% paraformaldehyde in 0.1 M phosphate buffer for five minutes
at a pressure of 180 mm Hg. The left kidneys were removed and
sliced into 1 mm slices. Every second slice (in order with a random
start) was post-fixed in 10% buffered formalin and processed for
embedding in glycolmethacrylate (Polaron Embedding Medium;
Bio-Rad Laboratories). Randomly selected cubes of cortical
tissue from the remaining 1 mm slices were immersion-fixed in
2.5% glutaraldehyde for three hours, post-fixed in 2.5% osmium
tetroxide for one hour, dehydrated through graded acetone
solutions and embedded in epon-araldite. The remaining tissue
was immersion-fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer and processed for embedding in paraffin for qualitative
assessment of glomerular morphology.
Estimation of kidney volume and glomerular volume
Recently developed unbiased stereological methods were used
to estimate kidney volume, mean glomerular tuft volume and
mean renal corpuscle volume. The kidney volume estimate is
unbiased because no assumption of kidney size or shape is
required. The glomerutar volume estimates are unbiased because
the stereological method employed does not require assumptions
of glomerular size, size uniformity, shape or orientation. All
glomeruli, regardless of size, contribute equally to the final
estimate. This is particularly important when studying a disease
that may involve alterations in glomerular size. These methods are
described briefly below. For more detailed descriptions and
explanatory figures see Bertram et a! [17] and Bertram [14].
Kidney slices (1 mm) embedded in glycolmethacrylate were
exhaustively sectioned at a nominal thickness of 20 im using a
Reichert-Jung Supercut microtome. Beginning with a random
number, every 10th section and the section following it (11th
section) were mounted on 1% gelatinised slides and stained with
Periodic acid-Schiff's (PAS) stain. Section thickness was measured
using a digital micrometer as described in [14].
Kidney volume (VkId) was estimated using the Cavalieri prin-
ciple [18]. Every tenth section was projected onto an orthogonal
grid at a magnification of )< 19.2 using a Fuji Minicopy Reader.
Kidney volume was estimated using:
Vkd 2 X 10 X t X a(p) X
where 2 was the inverse of the fraction of kidney slices sampled,
10 was the inverse of the fraction of sections sampled, t was mean
section thickness, a(p) was the area associated with each grid
point (approximately 1.8 mm2), and P, was the number of grid
points overlying the sections.
The total number of glomeruli per kidney (Ngjom kd) was
estimated using a physical disector/fractionator combination.
Only complete glycolmethacrylate sections were used; sections
that grazed the surface of a slice were not used. Two Olympus
BH-2 microscopes fitted with projection arms were used and each
pair of sections was viewed simultaneously at approximately ><150
(see Fig. 6 in Bertram [14]). One microscope was fitted with a
motorized stage, while the other was fitted with a rotating stage to
enable the two sections of each pair to be aligned. Fields were
sampled using the motorized stage, and for each field, those
glomeruli sampled by an unbiased counting frame in the reference
section (first section of a pair) but absent in the look-up section
(second section of the pair) were counted (see Fig. 1 in Bertram
et al [17]). This was repeated using the look-up section as the
reference section, doubling the efficiency of the procedure. The
total number of glomeruli in a kidney was estimated using:
Nglom,kid = 2 X 10 X (P/P1) X [lI(2fa)I >< Q
where 2 was the inverse of the slice sampling fraction, 10 was the
inverse of the section sampling fraction, S'f and 1/2f gave the
fraction of section area sampled (P1 was the number of grid points
falling on complete sections), and Q was the actual number of
glomeruli counted. Between 80 and 230 glomeruli were counted
for each kidney.
Using an orthogonal grid placed in the unbiased counting
frame, the number of points falling on kidney tissue and the
number of points falling on glomerular tuft and renal corpuscle
were counted. The volume densities in kidney of glomeruli and
renal corpuscles were then calculated using the formulae:
VVglom,Cd = Pglom/Pkid and
Vvp,ud =
"corpkid
Mean glomerular tuft volume and mean renal corpuscle volume
were then estimated using:
V&om Vvom/Nvom,
Vcorp = Vvcop,kid/NVg1om,Cd
Note that the numerical density of glomeruli in the kidney was
obtained by dividing Ngiom kid by Vkd.
Stereology of glomerular capillaries
For each kidney, five randomly selected epon-araldite blocks
were sectioned at 0.5 rm and stained with methylene blue. Two
glomeruli were sampled from each section. Incomplete or dam-
aged glomeruli, and those less than one glomerular diameter from
the section edge were not used. Where there were more than two
useable glomeruli in a section, the modulus sampling method of
Nyengaard [11] was used. Accordingly, each glomerulus was
allocated a number between 1 and k, where k was the number of
useable glomeruli. The first glomerulus was chosen using a
random number table, where the number chosen was r, and the
second glomerulus was chosen using the formula: r7 = r + (k/2).
If r2 was greater than k, then r2 — kwas used to select the second
glomerulus to be sampled.
For stereology of glomerular capillaries, an Olympus BH-2
microscope modified for projection and fitted with a X 100 oil
immersion lens (numerical aperture = 1.4) was used to project
the glomerular profiles onto an orthogonal grid at a final magni-
fication of approximately x 1,500. To estimate the area of the
renal corpuscle profile, the number of grid points falling on the
renal corpuscle (Pcørp) was counted and multiplied by the area
[a(p)] associated with each point (approximately 100 Lm2). The
length density of capillaries in renal corpuscle (Lvcapcorp) was
estimated by counting the number of capillary profiles within the
renal corpuscle profile (0) and using the standard stereological
formula [19]:
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Table 1. Body weight, kidney weight and stereological data for the four groups of rats
Week 7 Week 13
Saline (N 8) PAN (N = 6) Saline (N = 8) PAN (N = 7)
Body weightg
Kidney weightg
Kidney weight/body weight %
Sclerotic index
285 27
133 0.10
0.468 0.028
0.048 0.018
284 25
1.54 0.14
0.542 0.019
0.069 0.013
294 21
1.36 0.16
0.468 0.036
0.057 0.031
277 11
1.66 0.32
0.602 0.128
0.143 0.058
Glomerulosclerosis % 4.57 1.57 6.50 1.06 4.92 2.18 13.03 5.34
Ngiom kid
Vgiom xiO mm3Vcorp xIO mm3
Vvgiom,rp %
Lvc,p,corp mm/mm3
Lcap,corp mm
Svcapc,rp mm2/mm3
5cap,corp mm2
dcap pin
34376 4545
7.054 1.069
9.148 1.775
77.6 5.1
9611 1038
8.729 1.621
l70 14
0.154 0.024
5.61 0.42
29259 5072
10.446 2.578
12.905 2.688
79.3 7.1
9729 1070
12.702 3.640
195 19
0.254 0.069
6.39 0.61
29164 3273
7.896 0.796
10.621 1.244
74.6 5.3
9250 911
9.755 0.594
176 15
0.186 0.021
6.08 0.61
27468 5210
12.851 2.900
16.795 4.439
77.1 3.9
7201 1111
11.896 2.908
152 16
0.252 0.059
6.78 0.47
Values are mean standard deviation. The number of rats in each group is given in parenthesis.
= (2 X Q)/[P x a(p)]
From this the total length of capillaries in an average renal
corpuscle can be obtained:
Lcap,corp = Lcap,cp X V
The surface density of capillaries (surface area of capillaries per
unit volume of renal corpuscle, Sap,c,rp) was estimated by
counting the number of intersections (I) between the stereological
test grid and the capillary basement membranes, and then using
the standard stereological formula:
S10 = (2 x I)/(P0 x k x d)
where k is 2 for an orthogonal grid, and d is the length of each grid
line adjusted for magnification. The total surface area of capillar-
ies in an average renal corpuscle was then estimated using:
SpC()P = Svcap,rp >< V
The mean diameter of glomerular capillaries was estimated using
the formula:
= S,/(fl X Lcap,corp)
This estimate is not unbiased, as it assumes that the capillaries are
cylindrical.
Sclerotic index
A semiquantitative method was used to evaluate the frequency
and degree of glomerular sclerosis. Tissue was embedded in
paraffin, and 3 jm sections were cut and stained with Periodic
acid-Schiff's. Three sections from each kidney were evaluated.
Each section was sampled using a motorized microscope stage. A
graticule was placed in the eyepiece of the microscope to provide
an unbiased counting frame [20]. Glomerular profiles were sam-
pled if they fell within the unbiased counting frame. Glomerular
sclerosis was graded from 0 to 4, with 0 being a normal glomerular
profile, 1 a glomerular profile with up to a quarter of the area
being sclerotic, 2 a profile with between a quarter and a half
sclerotic, 3 a half to three-quarters of the area being sclerotic and
4, three-quarters to all of the profile being sclerotic. The sclerotic
index was calculated according to Saito et al [2fl:
SI. = [(nO X 0) + (ni X 1) + (n2 X 2)
+ (n3 >< 3) + (n4 x 4)11/total number of glomeruli counted
The percentage of glomeruli with sclerosis was also calculated.
Approximately 150 glomeruli from each rat were evaluated using
a blind experimental design.
Statistics
Data were analyzed using two-way analysis of variance. A
probability of 0.05 or less was accepted as statistically significant.
Data are means SD, except urinary protein excretion rates,
which are given as means SEM.
Results
Body and kidney weights
The body wts of saline-treated and PAN-treated rats were
similar throughout the experiment (Table 1). Treatment with
PAN significantly increased kidney weight at both weeks 7 and 13
(P < 0.05) (Table 1). Kidney weight to body wt ratio in PAN-
treated rats was significantly higher than in saline-treated rats at
both weeks 7 and 13 (P < 0.001).
Proteinuria
A daily protein excretion rate of less than 10 mg was considered
to be non-proteinuric. The daily protein excretion rate of rats
treated with saline never rose above 10 mg. Rats treated with
PAN became proteinuric at 15 days (1 day after the third injection
of PAN), when their protein excretion rate was 14.6 3.8 mg/day
(Fig. 1). Proteinuria in PAN-treated rats reached a maximum of
149.2 23.8 mg/day at week 11. Note that the protein excretion
rate rose after the injections of PAN at weeks 6, 8 and 10 (Fig. 1).
Sclerotic index
Two way analysis of variance indicated significant effects of both
time (P < 0.05) and PAN (P < 0.001) on sclerotic index. The
effect of PAN on sclerotic index changed with time (P < 0.05),
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indicating no effect at seven weeks and an effect at 13 weeks.
Values are given in Table 1. The percentage of glomerular profiles
with sclerotic segments also changed with both time (P < 0.05)
and PAN (P < 0.001), and again the effect of the PAN was only
observed at week 13 (P < 0.05). Representative photomicro-
graphs of glomeruli from the four treatment groups are shown in
Figure 2. At both weeks 7 and 13, the renal interstitium of
PAN-treated rats contained a moderate amount of cellular infil-
trate.
Glomerular volume
There were significant effects of both time (P < 0.05) and PAN
(P < 0.00 1) on mean glomerular tuft volume (VgI(,m, Table 1, Fig.
3A). Mean glomerular tuft volume in PAN-treated rats at seven
weeks was 48% greater than in saline-treated rats, and by 13
weeks mean glomerular tuft volume was 63% greater in PAN-
treated rats. Similarly, there were significant effects of both time
(P < 0.05) and PAN (P < 0.001) on mean renal corpuscle volume
(Vcç,rp; Table 1, Fig. 3B). The glomerular tuft comprised between
75% and 80% of the total renal corpuscle volume for each of the
four groups of rats.
Capillaty data
Analysis of variance indicated significant effects of both time
(P < 0.05) and PAN (P < 0.05) on the length of capillaries per
unit volume of renal corpuscle (Lvcapcorp; Table 1, Fig. 3C). At
seven weeks, capillary length density in saline and PAN-treated
rats was similar, but by 13 weeks the capillary length density was
significantly lower (approximately 22%) in PAN-treated rats.
Treatment with PAN significantly (P < 0.05) increased the mean
length of capillaries per glomerulus (Table 1, Fig. 3D). At seven
weeks, the length of capillaries in an average glomerulus from
PAN-treated rats was 4 mm greater than in saline-treated rats
(12.7 mm and 8.7 mm, respectively). At 13 weeks, an average
glomerulus from a PAN-treated rat contained 2 mm more capil-
lanes than a glomerulus from a saline-treated rat (11.9 mm and
9.7 mm, respectively).
Analysis of variance identified a significant effect of time (P <
0.05) on the surface density of capillaries (Svcap,corp; Table 1, Fig.
3E). There was a significant (P < 0.00 1) interaction between time
and PAN on this parameter. At seven weeks, the surface density
of capillaries was approximately 14% greater in PAN-treated rats
as compared to saline-treated rats, but at 13 weeks, the surface
density was approximately 13% less in PAN-treated rats. There
was a significant effect of PAN (P < 0.001) on the mean surface
area of capillaries per renal corpuscle (Scapc,rp; Table 1, Fig. 3F),
but there was no significant effect of time. Mean capillary surface
area was approximately 65% greater in PAN-treated rats at seven
weeks, and approximately 35% greater in PAN-treated rats at 13
weeks.
Analysis of variance indicated significant effects of time (P <
0.05) and PAN (P < 0.05) on mean glomerular capillary diameter.
Mean capillary diameter was approximately 14% greater in PAN-
treated rats as compared to saline-treated rats at seven weeks, and
11% greater in PAN-treated rats at 13 weeks.
Kidney volumes are shown in Figure 3H. Kidney volume
increased significantly (P < 0.05) following treatment with PAN.
Discussion
The four major findings of this study are: (1) glomerular
hypertrophy occurs in this PAN model of FSGS; (2) the glomer-
ular hypertrophy precedes the development of FSGS; (3) growth
of glomerular capillaries contributes significantly to glomerular
hypertrophy; and (4) the glomerular hypertrophy occurs in a
biphasic manner.
Glomerular hypertrophy has been reported in a variety of
experimental models of FSGS, and in many instances has been
shown to precede the development of FSGS. Mice which are
transgenic for bovine growth hormone have proportionately
larger glomeruli and a higher incidence of FSGS [7, 22], as do
mice which are transgenic for Simian virus 40 [23]. There are
many different models of renal ablation in rats which have
demonstrated glomerular hypertrophy [8—11]. Glomerular hyper-
trophy preceding the development of FSGS also occurs in rats
subjected to partial renal ablation and injections of adriamycin
[24]. In a study in which rats underwent either unilateral nephrec-
tomy or unilateral diversion of the ureter into the peritoneal
cavity, it was found that both groups of rats had increased
glomerular hypertension, hyperperfusion and hyperfiltration.
However, only rats which had undergone unilateral nephrectomy
developed glomerular hypertrophy and FSGS [25]. Following
subtotal nephrectomy, rats which are deficient for growth hor-
mone develop a lesser degree of glomerular hypertrophy and less
FSGS than Sprague-Dawley rats following subtotal nephrectomy
[26].
Data from human studies also suggests that glomerular hyper-
trophy may precede, or perhaps predispose to FSGS. In patients
post-renal transplant, those with larger glomeruli were more likely
to later develop FSGS, independent of the initial condition
requiring transplantation [5]. Patients with minimal change dis-
ease were found to have a greater likelihood of progressing to
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Fig. 1. Protein excretion rates from saline-treated (0) and PAN-treated (A)
rats. Values are mean SEM. Arrows indicate the times of injections.
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Fig. 2. Photomicrographs of representative glomeruli from the four experimental groups: A. PAN-treated rat, seven weeks; B. Saline-treated rat, seven weeks;
C. PAN-treated rat, 13 weeks; D. Saline-treated rat, 13 weekc. (Magnification X550; 0.5 sm epon-araldite sections stained with methylene blue.)
FSGS if they had larger glomeruli when initially biopsied [6].
Glomerular hypertrophy has been reported in patients with
glomerulosclerosis associated with oligomeganephronia [1],
diabetic ncphropathy [2], refiux nephropathy [31 and pre-eclamp-
sia [4].
The extent of glomerular hypertrophy identified in the present
study (48% at 7 weeks, 63% at 13 weeks) is surprising given that
glomerular hypertrophy has not been described previously in this
model. However, these results support the data of Trachtman Ct al
[271 who examined the effects of recombinant human growth
hormone (rhGH) administration on rats with FSGS induced using
this PAN model. They found that treatment with rhGH and PAN
resulted in glomerular hypertrophy and exacerbated the FSGS
induced by the PAN. The data of Trachtman et al [27] indicates
that glomerular hypertrophy did occur in rats treated with PAN
alone, although the authors did not specifically comment on this.
The glomerular hypcrtrophy observed in the present study
occurred in a biphasic manner. In the first phase (0 to 7 weeks),
the glomerular hypertrophy was due to an increase in the total
length of capillaries per glomerulus. In the second phase (7 to 13
weeks) the continued glomerular hypertrophy was not due to any
additional increase in glomerular capillary length. Rather, the
continued increase in glomerular volume that occurred in PAN-
treated rats between 7 and 13 weeks must be due to hypertrophy
C
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Fig. 3. Graphs indicating values (mean SD)
for eight stereological parameters for the four
groups of rats. The levels of statistical
significance come from two-way analysis of
variance. Abbreviations are: Int, interaction
between time and PAN; NS, not significant.
Symbols are: (Eli) saline treated; () PAN. P
values are: (A) PAN, P < 0.001; time, P <
0.05; Int, P = NS. (B) PAN, P < 0.001; time,
P < 0.05; Tnt, P = NS. (C) PAN, P < 0.05;
time, P < 0.05; Tnt, P < 0.05. (D) PAN, P <
0.05; time, P = NS; Tnt, P = NS. (E) PAN, P =
NS; time, P < 0.05; tnt, P < 0.001. (F) PAN,
P < 0.001; time, P = NS; Tnt, P = NS. (G)
PAN, P < 0.05; time, P < 0.05; Tnt, P = NS. (H)
PAN, P < 0.05; time, P = NS; Int, P = NS.
of other glomerular components, perhaps mesangial matrix or
capillary dilatation. We saw little evidence of mesangial matrix
expansion, but the stereological data indicates that glomerular
capillary diameter was greater in PAN-treated rats.
It is important to note that no attempt was made in the present
study to distinguish between juxtamedullary glomeruli and corti-
cal glomeruli. In rats, juxtamedullary glomeruli are much larger
than cortical glomeruli. Differences in the growth patterns of
these different suhpopulations of glomeruli may be worth analyz-
ing in future studies, as the juxtamedullary glomeruli appear to be
particularly susceptible to developing FSGS [28]. Of interest,
Kretzler, Koeppen-Hagemann, and Kriz [29] found that in a
unilateral nephrectomy/desoxycorticosterone model of FSGS,
when superficial and juxtamedullary glomeruli were measured
separately, the superficial glomeruli had undergone hypertrophy
to a much greater extent than the juxtamedullary glomeruli, so
that the final size of both populations of glomeruli was similar.
The mechanism by which glomerular hypertrophy leads to
FSGS remains unknown. Recently, Nagata and Kriz [30] analyzed
glomerular hypertrophy in rats following unilateral nephrectomy.
They described enlarged and dilated glomerular capillaries. They
postulated that this dilation of capillaries exerts mechanical stress
on the glomerular epithelial cells (podocytes), resulting in glomer-
ular epithelial cell injury. This results in detachment of the
glomerular epithelial cells from the glomerular basement mem-
brane. Nagata and Kriz [301 proposed that this area of denuded
glomerular basement membrane then attaches to the parietal
epithelial cells of Bowman's capsule, leading to an adhesion and a
segment of sclerosis. The inability or limited capacity of glomer-
ular epithelial cells to replicate [31, 32] is central to this theory.
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Experimental data from Fries et al [24] supports the central role
of limited glomerular epithelial cell division as the link between
glomerular hypertrophy and FSGS.
The events occurring in the present PAN model of FSGS differ
from those occurring in renal ablation models of FSGS as there is no
initial loss of nephrons. The mechanism by which PAN results in
glomerular hypertrophy is currently unknown. It is possible that PAN
initiates glomerular hypertrophy indirectly following its action on
glomerular epithelial cells. Since treatment with PAN leads to a loss
of glomerular epithelial cell foot processes and filtration slits, and an
increase in the permeability of the glomerular basement membrane
for proteins, the increase in capillary surface area seen here may
reflect an attempt by the glomerulus to increase the area available
for filtration and thus increase filtration capacity. Again, a fixed
number of glomerular epithelial cells must cover an amplified
glomerular capillary surface area. This may place "mechanical"
stress on the glomerular epithelial cells, leading to the sequence of
events proposed by Nagata and Kriz [301.
The present findings attest to the statistical power (ability to
detect a difference if one exists) and precision (low variance) of
the unbiased stereological methods employed. It is important to
emphasise that due to the unbiased nature of the stereological
methods used in this study all glomeruli, regardless of size, shape
or position in the kidney, have an equal chance of being sampled
and therefore measured. This is particularly important in a study
in which alterations in glomerular size are being examined. The
disector is the only known unbiased three-dimensional sampling
probe [33]. With the physical disector, which was used in the
present study, adjacent sections are examined simultaneously.
Glomeruli which are sampled by the unbiased counting frame in
the first section but are absent in the second section are counted.
Unbiased estimates of glomerular number and volume cannot be
obtained using single sections, as larger glomeruli are preferen-
tially sampled. Nyengaard et al [34] recently demonstrated that
estimates of glomerular volume obtained from single sections can
provide misleading information.
The present study has clearly demonstrated that glomerular
hypertrophy occurs in this PAN model of FSGS. The glomerular
hypertrophy precedes the development of FSGS, perhaps by as
much as six weeks. Glomerular hypertrophy has been observed in
many other models of FSGS, and appears to be a key event in the
development of FSGS. In the present model, the glomerular
hypertrophy is primarily due to capillary growth in the first seven
weeks (first phase), while in the second phase (7 to 13 weeks),
capillary growth does not contribute to the glomerular hypertro-
phy.
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